Intercept Pharmaceuticals Inc - Company Profile
Powered by 
All the sales intelligence you need on Intercept Pharmaceuticals Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Intercept Pharmaceuticals Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Intercept Pharmaceuticals Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Intercept Pharmaceuticals Inc (Intercept), a subsidiary of Alfasigma SpA, is a biopharmaceutical company focused on discovering, developing, and commercializing novel drugs for the treatment of progressive non-viral liver diseases with high unmet medical needs. The company's main activities involve leveraging research in bile acids and FXR agonism to expand its pipeline of treatments for serious liver diseases. Intercept's major product in development is INT-787, a next-generation farnesoid X receptor (FXR) agonist. The company is investigating INT-787 for its potential therapeutic applications in diseases such as severe alcohol-associated hepatitis (sAH) and primary biliary cholangitis (PBC). Intercept's products are primarily targeted at healthcare providers and patients dealing with liver diseases. The company conducts clinical trials across multiple sites in the US, UK, and France. Intercept Pharmaceuticals is headquartered in Morristown, New Jersey, USA.
Headquarters
United States of America
Address
305 Madison Avenue, Morristown, New Jersey, 07960
Website
www.interceptpharma.com
Telephone
1 646 7471000
No of Employees
341
Industry
Pharmaceuticals and Healthcare
Revenue (2022)
$353.9M
Intercept Pharmaceuticals Inc premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline Candidates: |
| INT-787: Severe Alcohol-Associated Hepatitis |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Contracts/Agreements | In January, the company renewed its research and development partnership with Tes Pharma. |
| 2023 | Acquisitions/Mergers/Takeovers | In November, the company got acquired by Alfasigma S.p.A. |
| 2023 | Regulatory Approval | In May, the company announced that the U.S. Food and Drug Administration granted orphan drug designation for the fixed-dose combination of obeticholic acid (OCA) and bezafibrate for the potential treatment of individuals with primary biliary cholangitis (PBC). |
Competitor Comparison
| Key Parameters | Intercept Pharmaceuticals Inc | AstraZeneca Plc | Novartis AG | Bristol-Myers Squibb Co | Novo Nordisk AS |
|---|---|---|---|---|---|
| Headquarters | United States of America | United Kingdom | Switzerland | United States of America | Denmark |
| City | Morristown | Cambridge | Basel | Princeton | Bagsvaerd |
| State/Province | New Jersey | Cambridgeshire | Basel-Stadt | New Jersey | - |
| No. of Employees | 341 | 96,100 | 75,267 | 32,500 | 64,974 |
| Entity Type | Private | Public | Public | Public | Public |
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Vivek Devaraj | Chairman; President - U.S. | Executive Board | 2024 | - |
| Rocco Venezia | Chief Financial Officer | Senior Management | 2023 | - |
| Jose Truzman | General Counsel - U.S. | Senior Management | 2023 | - |
| Victoria Carey | Head - U.S. Strategic Marketing; Senior Vice President | Senior Management | - | - |
| Deryk David | Head - U.S. Sales; Senior Vice President | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer